Samsung Biologics Selects Rockville for First U.S. Manufacturing Hub, Bolstering Maryland’s Life Sciences Sector

Governor Wes Moore announced that Samsung Biologics, a prominent South Korean biotechnology firm, has chosen Rockville, Maryland, for its inaugural United States manufacturing facility. This significant development follows an international trade and investment mission to Asia earlier this year, where Governor Moore and Maryland Department of Commerce Secretary Harry Coker met with Samsung Biologics executives to highlight Maryland’s economic strengths and workforce development potential. The move is poised to enhance the state’s already robust life sciences industry and create numerous job opportunities.

Samsung Biologics acquired an existing manufacturing facility in Rockville from GSK for $280 million. The company intends to expand the site’s drug substance production capacity and implement advanced technologies to meet the increasing demand for critical biologic medicines. This acquisition is expected to preserve more than 500 existing jobs at the facility and will also lead to the creation of new employment positions and provide opportunities for local suppliers. The expanded U.S. facility will be equipped for both clinical and commercial production of drug substances.

The strategic decision by Samsung Biologics to establish its U.S. base in Maryland underscores the state’s position as a leader in the life sciences sector. This investment is anticipated to strengthen collaborations with federal, state, and local entities, ensuring a reliable supply chain for life-saving therapeutics and advancing global healthcare. The company views this facility as a crucial step in its mission to improve lives through biomedicines and looks forward to integrating the existing workforce and contributing to the legacy of the Rockville site.

Maryland’s life sciences ecosystem, characterized by a high concentration of private companies, leading universities, and federal research facilities, makes it an attractive location for international biotechnology firms. Samsung Biologics’ presence will further solidify this cluster, fostering innovation and economic growth. The Department of Commerce plans to support Samsung Biologics throughout its transition and future expansion in the state.

The acquisition marks a substantial achievement for Montgomery County, bringing the world’s largest contract drug manufacturer to the region. This $280 million investment not only secures existing jobs but also positions the county for further growth in advanced manufacturing and reinforces its reputation as a global hub for life sciences. The established ecosystem, built on talent, diversity, and strong partnerships, is a key factor in attracting such significant international investment.

This announcement builds upon a series of major investments in Maryland’s biopharmaceutical sector over the past year. Notably, AstraZeneca recently committed $2 billion, the largest private capital investment in the state’s history, to expand manufacturing in Frederick and construct a new clinical facility in Gaithersburg, projected to create 2,600 jobs. The Moore-Miller Administration has also facilitated other significant investments, including an agreement with TEDCO to mobilize international co-investments in the state’s innovation economy. Additionally, Korean biotechnology company Nature Cell announced plans to open a stem cell manufacturing facility in Baltimore City, expected to generate approximately 500 new jobs. Earlier this year, Governor Moore welcomed Indian-based Syngene International for its first U.S. manufacturing site in Baltimore City, creating 300 jobs, and global wellness solutions company SJ Incorporation, which is expected to add 300 skilled positions in Washington County.

Article by Mel Anara, based upon information from the Office of Governor Wes Moore

---